Detalhe da pesquisa
1.
Correction to "Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study" [The Lancet Regional Health - Americas 2022; 16: 100366] https://doi.org/10.1016/j.lana.2022.100366.
Lancet Reg Health Am
; 18: 100422, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36593764
2.
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).
EClinicalMedicine
; 63: 102160, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37649806
3.
A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).
Lancet Reg Health Am
; 21: 100497, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37192953
4.
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study.
Lancet Reg Health Am
; 16: 100366, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36185968
5.
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen.
N Biotechnol
; 72: 11-21, 2022 Dec 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35953030
6.
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
EClinicalMedicine
; 46: 101383, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35434578
7.
Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors.
Heliyon
; 4(11): e00906, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30426104